Srinath Chinnakotla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Srinath Chinnakotla has a total of 243 co-authors. Here are the top co-authors by number of shared publications:
Melena D. Bellin
University of Minnesota Medical School
10 shared publications- Gregory J. Beilman
Department of Surgery, University of Minnesota, Minneapolis, Minnesota
8 shared publications - Ty Blink Dunn
Medical College of Wisconsin, Milwaukee, USA
8 shared publications Martin L. Freeman
University of Minnesota Medical School
7 shared publications- Melena D. Bellin
University of Minnesota Medical School
7 shared publications Timothy L. Pruett
Department of Surgery, University of Minnesota Medical School, Minneapolis, MN
7 shared publications
Latest Publications
- Open Access
- 21 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70380
ABO Incompatible Deceased Donor Liver Transplants in Infants (Age < 1 Year): A Single‐Center Experience
Background: The liver transplant waitlist mortality for infants (age < 1 year) is currently the highest, listed at 20 per 100 years of waiting time. ABO incompatible (ABOi) liver‐transplantation is one of the strategies to increase transplantation rate in infants but utilized only in 5.6% of infants. Methods: At our center, all children < 1 year are listed for ABOi liver transplants. If the anti‐ABO titers are less than 1:8, no plasmapheresis was used. Thymoglobulin is used for induction. We analyzed the transplant outcomes of patients that received ABOi livers compared to ABOc livers. Results: Sixteen infants, who received ABOi liver‐transplants are compared to 56 ABO‐compatible (ABOc) infant liver transplants. ABOi group utilized AB or B blood type livers 81%, compared to none in the ABOc group. The 1‐, 5‐, and 10‐year survival in the ABOi group remains at 81% and is comparable to survival in the ABOc group. None of the ABOi patients developed antibody‐mediated rejection or intrahepatic biliary strictures. None of the ABOi patients had hepatic artery thrombosis, compared with 4 (7.1%) in the ABOc group ( p = 0.64). There is no difference in infectious complications. The median wait times for patients < 1 year for blood types A, B, AB, and were 96, 109, 82 days and 126 respectively. The patients listed to accept ABOi livers had a shorter waiting time ( p = < 0.001). Conclusions: This study shows that ABOi liver transplants can be safely performed in children less than1 year of age without plasmapheresis, with excellent long‐term outcomes.
- 21 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70380
Open AccessABO Incompatible Deceased Donor Liver Transplants in Infants (Age < 1 Year): A Single‐Center Experience
Background: The liver transplant waitlist mortality for infants (age < 1 year) is currently the highest, listed at 20 per 100 years of waiting time. ABO incompatible (ABOi) liver‐transplantation is one of the strategies to increase transplantation rate in infants but utilized only in 5.6% of infants. Methods: At our center, all children < 1 year are listed for ABOi liver transplants. If the anti‐ABO titers are less than 1:8, no plasmapheresis was used. Thymoglobulin is used for induction. We analyzed the transplant outcomes of patients that received ABOi livers compared to ABOc livers. Results: Sixteen infants, who received ABOi liver‐transplants are compared to 56 ABO‐compatible (ABOc) infant liver transplants. ABOi group utilized AB or B blood type livers 81%, compared to none in the ABOc group. The 1‐, 5‐, and 10‐year survival in the ABOi group remains at 81% and is comparable to survival in the ABOc group. None of the ABOi patients developed antibody‐mediated rejection or intrahepatic biliary strictures. None of the ABOi patients had hepatic artery thrombosis, compared with 4 (7.1%) in the ABOc group ( p = 0.64). There is no difference in infectious complications. The median wait times for patients < 1 year for blood types A, B, AB, and were 96, 109, 82 days and 126 respectively. The patients listed to accept ABOi livers had a shorter waiting time ( p = < 0.001). Conclusions: This study shows that ABOi liver transplants can be safely performed in children less than1 year of age without plasmapheresis, with excellent long‐term outcomes.
- 25 May 2026
- Published by Springer Nature
- p. 1-8
History of Total Pancreatectomy with Islet Autotransplantation
- 25 May 2026
- Published by Springer Nature
- p. 1-8
History of Total Pancreatectomy with Islet Autotransplantation
- Open Access
- 29 April 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (5) , e70549
Hypoglycemia Occurrence and Risk Factors in Insulin Independent Patients After Total Pancreatectomy With Islet Autotransplantation
Background: Total pancreatectomy with islet auto‐transplantation (TPIAT) alleviates pain and preserves islet function in patients with severe pancreatitis. Although approximately one third of recipients achieve insulin independence, spontaneous hypoglycemia has been observed in this population. Its frequency, risk factors, and management remain poorly characterized. Methods: Using prospectively collected data on insulin‐independent (TPIAT) recipients at the University of Minnesota (2010–2023), we compared patients who developed hypoglycemia (defined as documented blood glucose < 70 mg/dL) to those with no reported hypoglycemia. Demographic, clinical, surgical, and metabolic variables were evaluated, and treatment strategies were reviewed. Results: Among 503 TPIAT recipients, 156 (31%) achieved insulin independence; of these, 45 (28.8%) experienced hypoglycemia, including 32 (20.5%) with level 2 hypoglycemia (< 54 mg/dL). Severe hypoglycemia events requiring external assistance occurred in 25% of affected individuals. Hypoglycemia developed a mean of 2.4 ± 2.2 years posttransplant, most commonly postprandial or exercise‐related. Patients who developed hypoglycemia were older at the time of TPIAT ( p = 0.036) and had higher preoperative BMI ( p = 0.016) and a greater prevalence of malabsorptive disorders ( p < 0.001), whereas islet yield and metabolic testing results were similar between patients with and without hypoglycemia. Most patients with hypoglycemia (78%) were managed with non‐pharmacological interventions (dietary, continuous glucose monitoring); pharmacologic therapies included acarbose (22%), diazoxide (13%), and minidose glucagon (7%). Conclusions: Spontaneous hypoglycemia is a frequent, clinically relevant complication among insulin‐independent TPIAT recipients. Older age, higher BMI, and malabsorptive disorders were associated with increased susceptibility. Routine surveillance, dietary counseling, and continuous glucose monitoring (CGM) are common components of management.
- 29 April 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (5) , e70549
Open AccessHypoglycemia Occurrence and Risk Factors in Insulin Independent Patients After Total Pancreatectomy With Islet Autotransplantation
Background: Total pancreatectomy with islet auto‐transplantation (TPIAT) alleviates pain and preserves islet function in patients with severe pancreatitis. Although approximately one third of recipients achieve insulin independence, spontaneous hypoglycemia has been observed in this population. Its frequency, risk factors, and management remain poorly characterized. Methods: Using prospectively collected data on insulin‐independent (TPIAT) recipients at the University of Minnesota (2010–2023), we compared patients who developed hypoglycemia (defined as documented blood glucose < 70 mg/dL) to those with no reported hypoglycemia. Demographic, clinical, surgical, and metabolic variables were evaluated, and treatment strategies were reviewed. Results: Among 503 TPIAT recipients, 156 (31%) achieved insulin independence; of these, 45 (28.8%) experienced hypoglycemia, including 32 (20.5%) with level 2 hypoglycemia (< 54 mg/dL). Severe hypoglycemia events requiring external assistance occurred in 25% of affected individuals. Hypoglycemia developed a mean of 2.4 ± 2.2 years posttransplant, most commonly postprandial or exercise‐related. Patients who developed hypoglycemia were older at the time of TPIAT ( p = 0.036) and had higher preoperative BMI ( p = 0.016) and a greater prevalence of malabsorptive disorders ( p < 0.001), whereas islet yield and metabolic testing results were similar between patients with and without hypoglycemia. Most patients with hypoglycemia (78%) were managed with non‐pharmacological interventions (dietary, continuous glucose monitoring); pharmacologic therapies included acarbose (22%), diazoxide (13%), and minidose glucagon (7%). Conclusions: Spontaneous hypoglycemia is a frequent, clinically relevant complication among insulin‐independent TPIAT recipients. Older age, higher BMI, and malabsorptive disorders were associated with increased susceptibility. Routine surveillance, dietary counseling, and continuous glucose monitoring (CGM) are common components of management.
- 31 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (9) , 2042-2046
Achieving zero waitlist mortality for children on the pediatric liver transplant waitlist
- 31 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (9) , 2042-2046
Achieving zero waitlist mortality for children on the pediatric liver transplant waitlist
- 1 February 2026
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 22 (1) , 91-110
Post-operative opioid consumption in pediatric solid organ transplant recipients: A single-site retrospective evaluation
Background: There is a paucity of data depicting post-operative opioid consumption in pediatric solid organ transplant (SOT) recipients, limiting ability to perform power analyses in designing prospective trials focusing on analgesia or adjuvant therapies in these populations. There is additionally unclear effect magnitude of various confounders of analgesic and sedative medications encountered in the pediatric intensive care unit (PICU). Methods: Retrospective review of pediatric patients aged 2 months-18 years at a single institution was performed on 137 SOT recipients (cardiac, liver, renal, total pancreatectomy with islet cell autotransplantation [TPIAT]) to evaluate post-operative opioid consumption in the PICU, analgesic confounders, pain scores, and opioid-related adverse effects (constipation, ileus, pruritus, nausea, urinary retention, delirium, respiratory depression, withdrawal). Values for correlative and multiplicative effect magnitude were analyzed for planned variables. Results: Average daily opioid requirement in oral morphine equivalents per kilogram was (cardiac) 12.5 (median 6.98, interquartile range [IQR] 14.3), (liver) 12.6 (median 10.1, IQR 15.3), (renal) 1.47 (median 0.614, IQR 0.95), and (TPIAT) 4.1 (median 3.44, IQR 2.6). Mechanical ventilation dependence, extracorporeal membrane oxygenation use, and open abdomen or chest demonstrated the highest correlation and effect magnitudes with opioid consumption of variables evaluated. No trends were identified for opioid-related adverse effects. Conclusion: Children receiving SOT have high opioid consumption relative to many populations in the PICU. Control for and evaluation of pain confounders such as mechanical ventilation and extracorporeal membrane oxygenation should be utilized in prospective studies analyzing opioid use, adjuvant analgesics, or outcomes in critically ill transplant recipients.
- 1 February 2026
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 22 (1) , 91-110
Post-operative opioid consumption in pediatric solid organ transplant recipients: A single-site retrospective evaluation
Background: There is a paucity of data depicting post-operative opioid consumption in pediatric solid organ transplant (SOT) recipients, limiting ability to perform power analyses in designing prospective trials focusing on analgesia or adjuvant therapies in these populations. There is additionally unclear effect magnitude of various confounders of analgesic and sedative medications encountered in the pediatric intensive care unit (PICU). Methods: Retrospective review of pediatric patients aged 2 months-18 years at a single institution was performed on 137 SOT recipients (cardiac, liver, renal, total pancreatectomy with islet cell autotransplantation [TPIAT]) to evaluate post-operative opioid consumption in the PICU, analgesic confounders, pain scores, and opioid-related adverse effects (constipation, ileus, pruritus, nausea, urinary retention, delirium, respiratory depression, withdrawal). Values for correlative and multiplicative effect magnitude were analyzed for planned variables. Results: Average daily opioid requirement in oral morphine equivalents per kilogram was (cardiac) 12.5 (median 6.98, interquartile range [IQR] 14.3), (liver) 12.6 (median 10.1, IQR 15.3), (renal) 1.47 (median 0.614, IQR 0.95), and (TPIAT) 4.1 (median 3.44, IQR 2.6). Mechanical ventilation dependence, extracorporeal membrane oxygenation use, and open abdomen or chest demonstrated the highest correlation and effect magnitudes with opioid consumption of variables evaluated. No trends were identified for opioid-related adverse effects. Conclusion: Children receiving SOT have high opioid consumption relative to many populations in the PICU. Control for and evaluation of pain confounders such as mechanical ventilation and extracorporeal membrane oxygenation should be utilized in prospective studies analyzing opioid use, adjuvant analgesics, or outcomes in critically ill transplant recipients.
- Open Access
- 14 October 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (10) , e70297
Twenty‐Year Kidney Transplant Outcomes With Prednisone‐Free Maintenance Immunosuppression: A Matched Control Analysis
There has been concern about long‐term outcomes of kidney transplant recipients treated with prednisone‐free maintenance immunosuppression. We studied 20‐year outcomes for recipients treated with discontinuation of prednisone p = 0.02); there was no difference in graft or death‐censored graft survival. For LD recipients, there was no difference between groups for all outcomes. Kidney transplant recipients treated with RDP had better or similar long‐term outcomes as those treated with long‐term MP. RDP should be considered for the majority of kidney transplant recipients.
- 14 October 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (10) , e70297
Open AccessTwenty‐Year Kidney Transplant Outcomes With Prednisone‐Free Maintenance Immunosuppression: A Matched Control Analysis
There has been concern about long‐term outcomes of kidney transplant recipients treated with prednisone‐free maintenance immunosuppression. We studied 20‐year outcomes for recipients treated with discontinuation of prednisone p = 0.02); there was no difference in graft or death‐censored graft survival. For LD recipients, there was no difference between groups for all outcomes. Kidney transplant recipients treated with RDP had better or similar long‐term outcomes as those treated with long‐term MP. RDP should be considered for the majority of kidney transplant recipients.
- 11 July 2025
- Published by Wolters Kluwer Health in Transplantation
- Vol. 109 (11) , 1765-1773
Liver Retransplantation: Identifying Factors and Developing a Risk Prediction Model to Predict Futility in the Modern Era
Background.: Liver retransplantation (rLT) results have traditionally been inferior compared with those of primary liver transplantation. Understanding the risks and anticipated outcomes is essential for patient counseling and obtaining informed consent. Methods.: Using the Scientific Registry of Transplant Recipients database, we analyzed a large cohort of adult rLT cases in the contemporary era to identify variables associated with posttransplant outcomes (with a focus on 1- and 5-y survival). Model predictions were made with random survival forests, a machine learning approach integrated into survival analysis. The difference in the out-of-bag C-index between a model with and without the variable was used to define variable importance. A prospective holdout cohort was used to validate the model predictions. Results.: Of the 3774 patients studied, the overall adjusted 1- and 5-y patient survival rates increased from 76.3% and 63.0%, respectively, for those transplanted in 2010, to 81.1% and 67.4% in 2019, then decreased to 78.0% and 63.9%, respectively, in 2022. The most important predictors of posttransplant mortality include recipient characteristics (being on life support before transplant, number of previous liver transplants, age, body mass index, and Karnofsky score) and donor organ characteristics (cold ischemia time and donor age). In a prospective validation cohort stratified into risk tertiles, the high-risk group had significantly lower 1-y survival (63.7%) compared with medium-risk (83.2%) and low-risk (88.7%, P < 0.001) groups. We developed a user-friendly online application using recipient and donor characteristics to predict 1- and 5-y survival. Conclusions.: The study model could be used as an additional tool to predict 1- and 5-y patient survival to help counsel prospective rLT candidates and guide donor selection in this technically challenging recipient group.
- 11 July 2025
- Published by Wolters Kluwer Health in Transplantation
- Vol. 109 (11) , 1765-1773
Liver Retransplantation: Identifying Factors and Developing a Risk Prediction Model to Predict Futility in the Modern Era
Background.: Liver retransplantation (rLT) results have traditionally been inferior compared with those of primary liver transplantation. Understanding the risks and anticipated outcomes is essential for patient counseling and obtaining informed consent. Methods.: Using the Scientific Registry of Transplant Recipients database, we analyzed a large cohort of adult rLT cases in the contemporary era to identify variables associated with posttransplant outcomes (with a focus on 1- and 5-y survival). Model predictions were made with random survival forests, a machine learning approach integrated into survival analysis. The difference in the out-of-bag C-index between a model with and without the variable was used to define variable importance. A prospective holdout cohort was used to validate the model predictions. Results.: Of the 3774 patients studied, the overall adjusted 1- and 5-y patient survival rates increased from 76.3% and 63.0%, respectively, for those transplanted in 2010, to 81.1% and 67.4% in 2019, then decreased to 78.0% and 63.9%, respectively, in 2022. The most important predictors of posttransplant mortality include recipient characteristics (being on life support before transplant, number of previous liver transplants, age, body mass index, and Karnofsky score) and donor organ characteristics (cold ischemia time and donor age). In a prospective validation cohort stratified into risk tertiles, the high-risk group had significantly lower 1-y survival (63.7%) compared with medium-risk (83.2%) and low-risk (88.7%, P < 0.001) groups. We developed a user-friendly online application using recipient and donor characteristics to predict 1- and 5-y survival. Conclusions.: The study model could be used as an additional tool to predict 1- and 5-y patient survival to help counsel prospective rLT candidates and guide donor selection in this technically challenging recipient group.
- Open Access
- 2 June 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (6)
Defining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation
Introduction: Targets for continuous glucose monitoring (CGM) are well established for type 1 and type 2 diabetes. In total pancreatectomy with islet autotransplantation (TPIAT), stricter glycemic targets are needed to avoid metabolic stress on transplanted islets, but no guidelines exist for CGM targets. Methods: We aimed to determine CGM targets for TPIAT clinical management by associating CGM metrics with goal hemoglobin A1c (HbA1c) ≤ 6.5%. Targets for time in range (TIR) 70–140, TIR 70–180, mean CGM glucose, and time in hyperglycemia (>140, >180, >250 mg/dL) were chosen to give good sensitivity and specificity for identifying HbA1c ≤6.5%. Results: We included 256 pairs of 14‐day CGM metrics with a concurrent HbA1c value ( n = 82 patients, age 35 [IQR 19–46] years at surgery, 70% female) who were ≥0.5 years post TPIAT (median 4.1 years) and wearing Dexcom G6. Most patients had more than one HbA1c and corresponding CGM available (median 2 [IQR 1–4] per patient). Conclusion: We found that TIR 70–140 ≥ 50% and TIR 70–180 mg/dL ≥ 75% may be reasonable minimum targets for patients and providers using CGM data to manage diabetes long‐term after TPIAT. Failure to meet these targets should prompt starting or adjusting insulin therapy, especially if hypoglycemia is not a concern.
- 2 June 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (6)
Open AccessDefining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation
Introduction: Targets for continuous glucose monitoring (CGM) are well established for type 1 and type 2 diabetes. In total pancreatectomy with islet autotransplantation (TPIAT), stricter glycemic targets are needed to avoid metabolic stress on transplanted islets, but no guidelines exist for CGM targets. Methods: We aimed to determine CGM targets for TPIAT clinical management by associating CGM metrics with goal hemoglobin A1c (HbA1c) ≤ 6.5%. Targets for time in range (TIR) 70–140, TIR 70–180, mean CGM glucose, and time in hyperglycemia (>140, >180, >250 mg/dL) were chosen to give good sensitivity and specificity for identifying HbA1c ≤6.5%. Results: We included 256 pairs of 14‐day CGM metrics with a concurrent HbA1c value ( n = 82 patients, age 35 [IQR 19–46] years at surgery, 70% female) who were ≥0.5 years post TPIAT (median 4.1 years) and wearing Dexcom G6. Most patients had more than one HbA1c and corresponding CGM available (median 2 [IQR 1–4] per patient). Conclusion: We found that TIR 70–140 ≥ 50% and TIR 70–180 mg/dL ≥ 75% may be reasonable minimum targets for patients and providers using CGM data to manage diabetes long‐term after TPIAT. Failure to meet these targets should prompt starting or adjusting insulin therapy, especially if hypoglycemia is not a concern.
- 17 March 2025
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 240 (4) , 405-413
Long-Term Islet Graft Functional Assessment in More than 500 Patients Undergoing Total Pancreatectomy with Intraportal Islet Autotransplantation
BACKGROUND: Total pancreatectomy and intraportal islet cell autotransplantation (TPIAT) is increasingly being offered to patients with refractory chronic pancreatitis. Understanding factors that affect islet function over time is critical. STUDY DESIGN: We evaluated factors associated with islet function during 12 years post-TPIAT using mixed meal tolerance testing. Insulin independence and HbA1c were assessed at each time. We compared area under the curve (AUC) C-peptide, AUC glucose, insulin–independent, and hemoglobin A1c patterns over time by patient characteristics using generalized linear mixed models. RESULTS: A total of 555 patients (median age 32 [interquartile range 17 to 45] years, 25% pediatric; 70% women, 41% overweight or obese) undergoing TPIAT were studied. A median islet equivalents per kg (IEQ/kg) transplanted was 3,696 (interquartile range 2,449 to 5,494) with 26% receiving low (less than 2,500 IEQ/kg), 43% moderate (2,500 to 5,000 IEQ/kg), and 31% high islet mass (more than 5,000 IEQ/kg). AUC C-peptide immediately post-TPIAT was lowest in those with low islet mass and remained low over time. AUC C-peptide showed a modest increase in islet function more than 3 to 4 years in moderate or high islet mass, followed by decline (p < 0.0001 for difference in post-TPIAT trajectory by group). Children have better long-term islet function, particularly beyond 5 years post-TPIAT, although the difference did not reach statistical significance (p = 0.0608); and overweight individuals have declining islet function long term, whereas those with normal or low BMI have gains in the first 3 to 5 years (p < 0.0001). Mean hemoglobin A1c was sustained at <7% for 8 years in high islet mass. CONCLUSIONS: In patients with high islet mass transplanted, islet function improves in the first several years after islet autotransplantation. Islet function is sustained longer in children than in adults. Overweight or obese body habitus may be detrimental to long-term islet function, highlighting the importance of maintaining a healthy body weight for TPIAT recipients.
- 17 March 2025
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 240 (4) , 405-413
Long-Term Islet Graft Functional Assessment in More than 500 Patients Undergoing Total Pancreatectomy with Intraportal Islet Autotransplantation
BACKGROUND: Total pancreatectomy and intraportal islet cell autotransplantation (TPIAT) is increasingly being offered to patients with refractory chronic pancreatitis. Understanding factors that affect islet function over time is critical. STUDY DESIGN: We evaluated factors associated with islet function during 12 years post-TPIAT using mixed meal tolerance testing. Insulin independence and HbA1c were assessed at each time. We compared area under the curve (AUC) C-peptide, AUC glucose, insulin–independent, and hemoglobin A1c patterns over time by patient characteristics using generalized linear mixed models. RESULTS: A total of 555 patients (median age 32 [interquartile range 17 to 45] years, 25% pediatric; 70% women, 41% overweight or obese) undergoing TPIAT were studied. A median islet equivalents per kg (IEQ/kg) transplanted was 3,696 (interquartile range 2,449 to 5,494) with 26% receiving low (less than 2,500 IEQ/kg), 43% moderate (2,500 to 5,000 IEQ/kg), and 31% high islet mass (more than 5,000 IEQ/kg). AUC C-peptide immediately post-TPIAT was lowest in those with low islet mass and remained low over time. AUC C-peptide showed a modest increase in islet function more than 3 to 4 years in moderate or high islet mass, followed by decline (p < 0.0001 for difference in post-TPIAT trajectory by group). Children have better long-term islet function, particularly beyond 5 years post-TPIAT, although the difference did not reach statistical significance (p = 0.0608); and overweight individuals have declining islet function long term, whereas those with normal or low BMI have gains in the first 3 to 5 years (p < 0.0001). Mean hemoglobin A1c was sustained at <7% for 8 years in high islet mass. CONCLUSIONS: In patients with high islet mass transplanted, islet function improves in the first several years after islet autotransplantation. Islet function is sustained longer in children than in adults. Overweight or obese body habitus may be detrimental to long-term islet function, highlighting the importance of maintaining a healthy body weight for TPIAT recipients.